Literature DB >> 16966357

Impact of ibuprofen therapy in the outcome of experimental pneumococcal acute otitis media treated with amoxicillin or erythromycin.

Gema del Prado1, Carmina Martínez-Marín, Lorena Huelves, Matilde Gracia, Violeta Rodríguez-Cerrato, Ricardo Fernández-Roblas, Carmen Ponte, Carlos Cenjor, Francisco Soriano.   

Abstract

The impact of ibuprofen combined with amoxicillin or erythromycin for therapy of penicillin-resistant pneumococcal acute otitis media (AOM) was evaluated in a gerbil model. Ibuprofen (at 2.5 or 7.5 mg/kg, orally) and/or amoxicillin or erythromycin (5 mg/kg each, s.c.) were administered at 5 h (early therapy, as single-dose regimen) or at 18 h (delayed therapy, five doses) postinoculation (PI). Each antibiotic alone and combined with ibuprofen was more effective administered as early regimen than as delayed treatment when evaluating the presence of otorrhea, otoscopic aspect, culture-positive and bacterial counts in middle ear (ME) samples, and loss of body weight. There was a trend for a better bacteriological outcome in animals receiving amoxicillin or erythromycin and ibuprofen, especially with the high dose. Such a dose of ibuprofen, associated with each antibiotic regimen, also preserved the animal well-being, avoiding a great weight loss in comparison to those receiving the antibiotic alone but a statistically significant difference was only observed for animals receiving delayed therapy with erythromycin and high-dose ibuprofen. In conclusion, ibuprofen combined with antibiotics seemed to improve the outcome of this experimental pneumococcal AOM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966357     DOI: 10.1203/01.PDR.0000242258.52590.b5

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  1 in total

1.  Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens.

Authors:  Parth N Shah; Kimberly R Marshall-Batty; Justin A Smolen; Jasur A Tagaev; Qingquan Chen; Christopher A Rodesney; Henry H Le; Vernita D Gordon; David E Greenberg; Carolyn L Cannon
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.